Biogen Licenses Immune Drug from Vanqua Bio
Biogen has licensed a preclinical immune drug from Vanqua Bio, a biotech company backed by OrbiMed, in a deal worth over $1 billion.
The drug is designed to inhibit "C5aR1", a protein that regulates inflammation and the immune system's response to pathogens and harmful cells.
- Biogen will pay $70 million upfront for exclusive worldwide rights to the drug.
- Vanqua Bio may receive up to $990 million more depending on development, regulatory, commercial, and sales goals.
- Vanqua Bio is also eligible for tiered royalties on net sales if the drug comes to market.
Biogen will lead all future development, manufacturing, and commercialization efforts.
Author's summary: Biogen licenses Vanqua Bio's immune drug for over $1 billion.
More News
- Telcos and ISPs: The time to prioritise cyber security is now
- Commuters on the Auckland City Rail Link will be able to access 5G phone connection from underground - 29-Oct-2025 - NZ Accident and Emergency news
- Nick Offerman and Lee K. Buchanan Close Out Arts and Humanities Day with a Love Letter to Carpentry, Family, and the Pursuit of Hands-On Work in the Digital Age
- Al-Nassr 1-2 Al-Ittihad: Report, result and goals as Karim Benzema scores to knock Cristiano Ronaldo's side out of Kings Cup
- Trump administration quietly purges ICE leaders in five cities, including Denver: Sources
- Charlie Kirk’s accused killer allowed to wear street clothes in court
- Nokia commits to full AI-RAN GPU play on new Nvidia RAN compute platform - The Mobile Network
- Nicole Kidman thriving while Keith Urban struggles after split
- Myrio Therapeutics Announces Collaboration with Leading Research Institutions to Advance Solid Tumor T cell Immunotherapeutics - FNArena.com
- Eintracht Frankfurt Borussia Dortmund 28 10 2025 Live Score and Match Summary